Maltopentaose (Maltopentose) |
| カタログ番号GC30268 |
マルトペンタオース (マルトペントース) は、マルトデキストリンとして分類できる最短鎖のオリゴ糖であり、α-ラクトアルブミンの糖化とリン酸化を調査する研究でも使用されています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 34620-76-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Maltopentaose (Maltopentose) is an oligosaccharide composed of five glucose units linked by α-1,4-glycosidic bonds[1]. Maltopentaose is the shortest oligosaccharide in maltodextrin and can be used to study the saccharification and phosphorylation of α-lactalbumin[2]. Maltopentaose can be used as a substrate for porcine pancreatic α-amylase (PPA) to study various inhibitors of PPA[3]. Maltopentaose has good biocompatibility and biodegradability and can be used as a carrier for drug delivery systems[4]. Maltopentaose has the function of regulating intestinal flora and can promote the growth of probiotics (such as bifidobacteria and lactic acid bacteria)[5]. Maltopentaose can be used as a carbon source for microbial culture and fermentation process optimization[6].
References:
[1] Chen S, Zhang Z, Yan Z, et al. Nigerooligosaccharides and Kojioligosaccharides[M]//Biomanufacture of Functional Carbohydrates. CRC Press, 2024: 147-179.
[2] Schong E, Famelart M H. Dry heating of whey proteins[J]. Food Research International, 2017, 100: 31-44.
[3] Desseaux V, Koukiekolo R, Moreau Y, et al. Mechanism of porcine pancreatic alpha-amylase: inhibition of amylose and maltopentaose hydrolysis by various inhibitors[J]. BIOLOGIA-BRATISLAVA-, 2002, 57(SUP/2): 163-170.
[4] Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres[J]. Advanced drug delivery reviews, 2012, 64: 316-326.
[5] Sharma D, Dhiman A, Thakur A, et al. Functional oligosaccharides as a promising food ingredient: a gleam into health apprehensions and techno-functional advantages[J]. Journal of Food Measurement and Characterization, 2024: 1-32.
[6] Bláhová M, Štefuca V, Hronská H, et al. Maltooligosaccharides: properties, production and applications[J]. Molecules, 2023, 28(7): 3281.
| Cas No. | 34620-76-3 | SDF | |
| Canonical SMILES | O[C@H]1[C@@H]([C@H](O[C@H](O[C@]([C@@H]2O)([H])[C@H](O[C@H](O[C@@]([C@H](O)CO)([H])[C@H](O)[C@@H](O)C=O)[C@@H]2O)CO)[C@@H]1O)CO)O[C@@]([C@@H]([C@@H](O)[C@@H]3O[C@@]([C@@H]([C@@H](O)[C@@H]4O)O)([H])O[C@@H]4CO)O)([H])O[C@@H]3CO | ||
| Formula | C30H52O26 | M.Wt | 828.72 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,PBS (pH 7.2): 2 mg/ml | Storage | -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2067 mL | 6.0334 mL | 12.0668 mL |
| 5 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL |
| 10 mM | 0.1207 mL | 0.6033 mL | 1.2067 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *